Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

Clinical Trial ID NCT01008358

Rank	Title	Journal	Year	PubWeight™‹?›
1	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.	J Hepatol	2013	2.63
2	Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.	Gastroenterology	2013	2.21
3	Retracted The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.	Biomed Res Int	2015	1.40
4	Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.	Hepatology	2014	1.16
5	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.	J Hematol Oncol	2016	1.12
6	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
7	Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.	Acta Pharmacol Sin	2015	0.92
8	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.	World J Hepatol	2015	0.88
9	Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma.	J Clin Cell Immunol	2015	0.84
10	Immunotherapy for solid tumors--a review for surgeons.	J Surg Res	2013	0.83
11	Modulation of CTLA-4 and GITR for cancer immunotherapy.	Curr Top Microbiol Immunol	2011	0.80
12	Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.	Toxins (Basel)	2016	0.78
13	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?	World J Gastroenterol	2016	0.76
14	Tremelimumab.	Drugs R D	2010	0.75